NCT05478694 Outcomes of Focal Ablation for Prostate Cancer
| NCT ID | NCT05478694 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 225 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 225 participants in total. It began in 2023-02-01 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
Eligibility Criteria
Inclusion Criteria: * Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy * Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease * Age 18-90 years. * Life expectancy \> 1 year * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Anatomic abnormalities that do not allow for focal ablation * Evidence of non-organ confined disease that is not feasible for ablation * Has active urinary traction infection
Contact & Investigator
Daniel Segal, M.D.
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT05478694 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 90 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05478694 currently recruiting?
Yes, NCT05478694 is actively recruiting participants. Contact the research team at Sonobia.Garrett@UTSouthwestern.edu for enrollment information.
Where is the NCT05478694 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT05478694 clinical trial?
NCT05478694 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Daniel Segal, M.D. at University of Texas Southwestern Medical Center. The trial plans to enroll 225 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.